Aoife Brennan is a biotech executive with extensive experience in drug development and a commitment to advancing treatments for rare and neglected diseases. Between 2014 and 2016, Aoife held senior roles at Biogen, including VP of the Rare Disease Innovation Unit, while currently serving on the boards of Critical Path Institute and FibroGen. Aoife is also the CEO and President of Climb Bio and Synlogic, Inc., demonstrating a strong focus on innovation and mentorship in the field. With a medical education from prestigious institutions such as Harvard Medical School and Trinity College Dublin, Aoife's expertise spans clinical research and leadership in the biotech industry.
Location
Cambridge, United States
This person is not in the org chart
This person is not in any teams